Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Pyxis Oncology has a “Moderate Buy” consensus rating from 10 analysts: eight buys, one hold and one sell. The average 12-month price target is $8.75.
• Analyst price targets were mixed, with Wells Fargo raising its target to $19, while Leerink Partners cut its target to $7; other firms set targets between $8 and $8.00.
• Shares opened at $2.14 and have declined 2.3%, while the company reported a quarterly loss of $0.40 per share, missing the $0.35 consensus estimate.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.75.

A number of research firms recently weighed in on PYXS. Leerink Partners reduced their price target on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating for the company in a report on Thursday, July 2nd. Wells Fargo & Company upped their price target on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. HC Wainwright raised their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Wedbush lifted their price objective on Pyxis Oncology from $6.00 to $8.00 and gave the stock an "outperform" rating in a report on Thursday, September 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Pyxis Oncology in a research note on Friday, September 25th.

Pyxis Oncology Trading Down 2.3%

Shares of Pyxis Oncology stock opened at $2.14 on Friday. The firm's 50 day simple moving average is $3.18 and its two-hundred day simple moving average is $2.40. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55. The firm has a market capitalization of $178.50 million, a price-to-earnings ratio of -1.52 and a beta of 1.37.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). On average, sell-side analysts predict that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company's stock valued at $1,297,000 after purchasing an additional 160,300 shares in the last quarter. 683 Capital Management LLC grew its holdings in shares of Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company's stock worth $1,026,000 after buying an additional 366,910 shares in the last quarter. Finally, J. Derek Lewis & Associates Inc. purchased a new stake in shares of Pyxis Oncology during the fourth quarter worth $61,000. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc NASDAQ: PYXS is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company's approach is centered on creating antibody-based medicines designed to selectively target tumor cells or the tumor microenvironment while delivering therapeutic activity intended to improve cancer treatment outcomes.

Pyxis Oncology's pipeline has included PYX-201, an antibody-drug conjugate designed to target extra-domain B fibronectin, a protein associated with the tumor microenvironment, and PYX-106, an investigational antibody targeting SIGLEC-15, an immune-regulatory protein expressed in several cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.